Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KVA 12123

X
Drug Profile

KVA 12123

Alternative Names: KVA-001; KVA-002; KVA-12.1; KVA-12123

Latest Information Update: 22 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GigaGen
  • Developer Kineta
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Acute myeloid leukaemia; Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 19 Aug 2024 Kineta plans to initiate a phase II trial for Solid tumours (Late-stage disease) in the end of 2024 2024
  • 08 Jul 2024 TuHURA Biosciences enters into an agreement to acquire KVA 12123 from Kineta
  • 08 May 2024 Kineta has patent protection for KV001 in USA, Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Korea, Mexico, Russia, and Singapore

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top